Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, Rapisa Nantanee, Pimpayao Sodsai, Orawan Himananto, Jiratchaya Sophonphan, Pintip Suchartlikitwong, Narin Hiransuthikul, Pornpimon Angkasekwinai, Auchara Tangsathapornpong, Nattiya Hirankarn the study team
doi: https://doi.org/10.1101/2022.02.15.22270974
Sira Nanthapisal
aDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
lResearch Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
mClinical Research Center, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thanyawee Puthanakit
bCenter of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thanyawee.p@chula.ac.th
Peera Jaru-Ampornpan
cVirology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rapisa Nantanee
bCenter of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
dPediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pimpayao Sodsai
eCenter of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orawan Himananto
fMonoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiratchaya Sophonphan
gThe HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pintip Suchartlikitwong
hDepartment of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narin Hiransuthikul
iDepartment of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pornpimon Angkasekwinai
jDepartment of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumthani, Thailand
kResearch Unit in Molecular Pathogenesis and Immunology of Infectious Diseases, Thammasat University, Pathumthani, Thailand
lResearch Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Auchara Tangsathapornpong
aDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
lResearch Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nattiya Hirankarn
eCenter of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed.

Objective To evaluate immunogenicity and reactogenicity of standard- versus low-dose ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults.

Methods A double-blinded, randomized, controlled trial of adult, aged 18-59 years, with completion of 2-dose CoronaVac at 21-28 days apart for more than 2 months was conducted. Participants were randomized to receive AZD1222 (Oxford/AstraZeneca) intramuscularly; standard dose (SD, 5×1010 viral particles) or low dose (LD, 2.5×1010 viral particles). Surrogate virus neutralization test (sVNT) against wild type and delta variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) were compared as geometric mean ratio (GMR) at day 14 and 90 between LD and SD arms.

Results From July-August 2021, 422 adults with median age of 44 (IQR 36–51) years were enrolled. The median interval from CoronaVac to AZD1222 booster was 77 (IQR 64–95) days. At baseline, geometric means (GMs) of sVNT against delta variant and anti-S-RBD IgG were 18.1%inhibition (95%CI 16.4-20.0) and 111.5 (105.1-118.3) BAU/ml. GMs of sVNT against delta variant and anti-S-RBD IgG in SD were 95.6%inhibition (95%CI 94.3-97.0) and 1975.1 (1841.7-2118.2) BAU/ml at day 14, and 89.4%inhibition (86.4-92.4) and 938.6 (859.9-1024.4) BAU/ml at day 90, respectively. GMRs of sVNT against delta variant and anti-S-RBD IgG in LD compared to SD were 1.00 (95%CI 0.98-1.02) and 0.84 (0.76–0.93) at day 14, and 0.98 (0.94-1.03) and 0.89 (0.79-1.00) at day 90, respectively. LD recipients had significantly lower rate of fever (6.8%vs25.0%) and myalgia (51.9%vs70.7%) compared to SD.

Conclusion Half-dose AZD1222 booster after 2-dose inactivated SARS-CoV-2 vaccination had non-inferior immunogenicity, yet lower systemic reactogenicity. Fractional low-dose AZD1222 booster should be considered especially in resource-constrained settings.

Highlights

  • - Low dose AZD1222 could boost comparable immunity to standard dose in healthy adult who completed 2 doses of inactivated SARS-CoV-2 vaccines.

  • - Less reactogenicity occurred in low-dose AZD1222 booster than standard-dose recipients.

HighlightsThai Clinical Trials Registry (thaiclinicaltrials.org): TCTR20210722003

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Thai Clinical Trials Registry: thaiclinicaltrials.org, TCTR20210722003.

Funding Statement

The study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under Health Research Platform (764002-HE07), Chulalongkorn University and Faculty of Medicine, Thammasat University. This research is also supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional review board of Faculty of Medicine, Thammasat University (MTU-EC-PE1-182/64) and Faculty of Medicine, Chulalongkorn University (IRB No. 600/64) approved this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵** Additional study team members are listed in the Acknowledgments.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

  • Abbreviations

    BAU
    Binding-antibody unit
    BMI
    Body mass index
    CMI
    Cell-mediated immunity
    ELISpot
    Enzyme-linked immunospot
    GM
    Geometric mean
    GMR
    Geometric mean ratio
    LD
    Low dose
    PBMC
    Peripheral blood mononuclear cell
    SFU
    Spot forming unit
    S-RBD
    Spike receptor binding domain
    SD
    Standard dose
    sVNT
    Surrogate virus neutralization test
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted February 15, 2022.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
    Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, Rapisa Nantanee, Pimpayao Sodsai, Orawan Himananto, Jiratchaya Sophonphan, Pintip Suchartlikitwong, Narin Hiransuthikul, Pornpimon Angkasekwinai, Auchara Tangsathapornpong, Nattiya Hirankarn
    medRxiv 2022.02.15.22270974; doi: https://doi.org/10.1101/2022.02.15.22270974
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
    Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, Rapisa Nantanee, Pimpayao Sodsai, Orawan Himananto, Jiratchaya Sophonphan, Pintip Suchartlikitwong, Narin Hiransuthikul, Pornpimon Angkasekwinai, Auchara Tangsathapornpong, Nattiya Hirankarn
    medRxiv 2022.02.15.22270974; doi: https://doi.org/10.1101/2022.02.15.22270974

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (271)
    • Allergy and Immunology (559)
    • Anesthesia (135)
    • Cardiovascular Medicine (1779)
    • Dentistry and Oral Medicine (240)
    • Dermatology (173)
    • Emergency Medicine (317)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
    • Epidemiology (10840)
    • Forensic Medicine (8)
    • Gastroenterology (595)
    • Genetic and Genomic Medicine (2970)
    • Geriatric Medicine (289)
    • Health Economics (534)
    • Health Informatics (1938)
    • Health Policy (837)
    • Health Systems and Quality Improvement (747)
    • Hematology (296)
    • HIV/AIDS (634)
    • Infectious Diseases (except HIV/AIDS) (12536)
    • Intensive Care and Critical Care Medicine (697)
    • Medical Education (300)
    • Medical Ethics (89)
    • Nephrology (325)
    • Neurology (2822)
    • Nursing (152)
    • Nutrition (436)
    • Obstetrics and Gynecology (561)
    • Occupational and Environmental Health (600)
    • Oncology (1476)
    • Ophthalmology (444)
    • Orthopedics (172)
    • Otolaryngology (259)
    • Pain Medicine (190)
    • Palliative Medicine (56)
    • Pathology (382)
    • Pediatrics (870)
    • Pharmacology and Therapeutics (368)
    • Primary Care Research (341)
    • Psychiatry and Clinical Psychology (2654)
    • Public and Global Health (5394)
    • Radiology and Imaging (1019)
    • Rehabilitation Medicine and Physical Therapy (599)
    • Respiratory Medicine (729)
    • Rheumatology (330)
    • Sexual and Reproductive Health (294)
    • Sports Medicine (280)
    • Surgery (330)
    • Toxicology (48)
    • Transplantation (151)
    • Urology (127)